The survival time of breast cancer is significantly related to the clinical stage of breast cancer. The 5-year survival rate of early-stage breast cancer is over 90%, the 5-year survival rate of mid-stage breast cancer given surgery plus adjuvant chemotherapy and radiotherapy is between 60% and 80%, and the 5-year survival rate of late-stage breast cancer is about 30%. In addition to the obvious relationship with breast staging, there is also a clear correlation with the biological characteristics of different types of patients. In recent years, molecular staging has been adopted to provide a better assessment of the prognosis of breast cancer, with a higher 5-year survival rate for hormone-sensitive positives than for negatives. The 5-year survival rate for HER-2 positive patients given targeted drug applications is significantly higher than those without targeted drugs by about 50%. The highest malignancy is triple negative breast cancer, with a 5-year survival rate of about 40%-50%, and is also the breast cancer with the worst prognosis